Ruxolitinib, sold in India as Jakavi, loses Indian patent protection on 12 December 2026. This market entry brief tells a generic entrant what it needs to know before that date: the patent and litigation position, the Indian companies already lined up, the regulatory route, how prices moved at recent Indian openings, and a launch checklist.
| Format | Market entry brief (PDF) |
| Molecule | Ruxolitinib (JAK inhibitor) |
| Indian patent expiry | 12 December 2026 (IN 269841) |
| Price control | Not in NLEM 2022 |
| Published | 17 November 2026, free update after first launches |
A full market report sizes a whole market. A market entry brief answers one decision: should we launch this molecule in India, and how. It is built for business development, portfolio and launch teams who need a clear answer before a date.
Related: India Drug Patent Expiry Calendar | India Drug Market Entry Tracker | CDSCO Decoded
1. Summary
2. Patent position
3. Who is lined up
4. Regulatory route
5. Price and price control
6. Who prescribes and buys
7. Entry checklist
8. What we will update